文献速递免疫规划卫生政策与健康促进

香港老年人接种佐剂带状疱疹亚单位疫苗的潜在成本效果

Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
PubMed 文献 · Vaccine · 2018-06-27

本研究采用终身马尔可夫模型,模拟香港50岁、60岁、70岁接种佐剂带状疱疹亚单位疫苗与不接种的成本效果。结果显示各接种策略相对于不接种的增量成本效果比为46,267-64,341美元/QALY,处于香港人均GDP的1-3倍之间;疫苗成本是影响ICER的最主要参数,各策略的成本效果高度取决于疫苗价格和支付意愿阈值。

要点

  • 50岁接种相比不接种可多获得0.00258 QALYs,增量成本166美元,ICER为46,267-64,341美元/QALY范围之一。
  • 各接种策略ICER介于香港人均GDP的1-3倍(43,530-130,590美元)之间。
  • 疫苗成本是使各策略ICER降至低于1倍人均GDP的最常见且影响最大的参数。

核心结论

  • 各接种策略的成本效果高度取决于疫苗成本与每QALY的支付意愿阈值。

研究设计与样本

  • 设计终身马尔可夫模型,模拟四种方案:入组时(50岁)接种、推迟至60岁接种、推迟至70岁接种和不接种。
  • 模型临床输入来自文献,带状疱疹治疗成本来自218例带状疱疹患者队列,并开展单因素和概率敏感性分析。

主要发现

  • 基础分析中,与不接种相比,50岁接种的QALY增益和增量成本最高(0.00258 QALYs;166美元),其次为推迟至60岁(0.00215 QALYs;102美元)和推迟至70岁(0.00134 QALYs;62美元)。
  • 各接种组相对于不接种的ICER为46,267-64,341美元/QALY,介于香港人均GDP的1-3倍(43,530-130,590美元)之间。
  • 单因素敏感性分析发现,疫苗成本是使各接种策略ICER降至低于1倍人均GDP的常见且影响最大的参数。
  • 概率敏感性分析中,在支付意愿阈值分别为78,400、57,680和53,760美元/QALY时,50岁接种、推迟至60岁和推迟至70岁接种分别在90%的运行中被接受为具有成本效果。

关键数值与推荐

  • 基础分析中,50岁接种相比不接种:QALY增益0.00258,增量成本166美元。
  • 推迟至60岁接种相比不接种:QALY增益0.00215,增量成本102美元。
  • 推迟至70岁接种相比不接种:QALY增益0.00134,增量成本62美元。
  • 各接种组相对于不接种的ICER为46,267-64,341美元/QALY,香港人均GDP为43,530-130,590美元。
  • 概率敏感性分析中,支付意愿阈值78,400美元/QALY时50岁接种、57,680美元/QALY时推迟至60岁接种、53,760美元/QALY时推迟至70岁接种分别在90%的运行中被接受为具有成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvanted herpes zoster (HZ) subunit vaccine is recommended for adults aged ≥50 years. This study aimed to investigate cost-effectiveness of HZ subunit vaccine for older adults at different age in Hong Kong. METHODS: A life-long Markov model was designed to simulate outcomes of four alternatives: Vaccination at model entry (age 50 years); deferring vaccination to 60 years; deferring vaccination to 70 years; and no vaccination. Outcome measures included direct cost, indirect cost, HZ and post-herpetic neuralgia incidences, quality-adjusted life years (QALYs) loss, and incremental cost per QALY saved (ICER). Model clinical inputs were derived from literature. HZ treatment costs were collected from a cohort of HZ patients (n = 218). One-way and probabilistic sensitivity analyses were performed. RESULTS: In base-case analysis, vaccination at 50 years showed highest QALYs saved and increment cost (0.00258; USD166), followed by deferring to 60 years (0.00215 QALYs saved; USD102) and deferring to 70 years (0.00134 QALYs; USD62) when comparing to no vaccination. ICERs of vaccination arms versus no vaccine (46,267-64,341 USD/QALY) were between 1-3 × gross domestic product (GPD) per capita in Hong Kong (USD43,530-USD130,590). One-way sensitivity analyses found vaccine cost to be the common and most influential parameter for ICER of each vaccination strategy to become <1 × GDP per capita. In probabilistic sensitivity analysis, vaccination at 50 years, deferring to 60 years and 70 years were accepted as cost-effective in 90% of time at willingness-to-pay (WTP) of 78,400 USD/QALY, 57,680 USD/QALY and 53,760 USD/QALY, respectively. CONCLUSIONS: Cost-effectiveness of each strategy is highly subject to the vaccine cost and WTP threshold per QALY saved.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. You JHS, Ming WK, Lee CF, et al. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong. Vaccine. 2018. PMID: 29958739. doi:10.1016/j.vaccine.2018.06.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。